Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19200906 | 0.88 | ACACB (0.71) | ACACBSMN1; SMN2HPGDGAAPOLB | |
| SCHEMBL20412852 | 0.88 | ACACB (0.56) | ACACBSMN1; SMN2HPGDGAAPOLB | |
| SCHEMBL13745505 | 0.86 | RECQL (0.73) | ACACBSMN1; SMN2HPGDGAAPOLB | |
| SCHEMBL6457656 | 0.84 | POLB (0.71) | ACACBSMN1; SMN2HPGDGAAPOLB | |
| SCHEMBL527596 | 0.84 | POLB (0.71) | ACACBSMN1; SMN2HPGDGAAPOLB | |
| SCHEMBL6922906 | 0.84 | POLB (0.71) | ACACBSMN1; SMN2HPGDGAAPOLB | |
| SCHEMBL23366573 | 0.83 | DRD2 (0.60) | GAARECQLTP53ALDH1A1LMNA | |
| SCHEMBL516876 | 0.82 | ACACB (0.62) | ACACBSMN1; SMN2HPGDGAAPOLB | |
| SCHEMBL516877 | 0.82 | ACACB (0.62) | ACACBSMN1; SMN2HPGDGAAPOLB | |
| Hydrochloric Acid SCHEMBL1953975 | 0.81 | ACACB (0.61) | ACACBSMN1; SMN2HPGDGAAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11168090-B2 | Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2021-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11168090-B2 | Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors | RET, BRAF, ROR1 | ACACB 4807/4885SMN1; SMN2 1115/4885HPGD 4011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.